Older men looking for the so-called “Fountain of Youth” probably can’t count on AndroGel and other prescription testosterone gels, according to a new study. The research, which appeared last month in the New England Journal of Medicine (NEJM), found that the medications provided only modest benefits in mitigating some affects of aging.

The publication of the landmark study comes as thousands of testosterone lawsuits involving AndroGel and similar medications make their way through U.S. courts. Plaintiffs in these cases allege that the drugs’ manufacturers concealed their association with an increased risk of heart attacks, strokes and blood clots, and failed to provide doctors and patients with appropriate warnings about these cardiovascular side effects. The lawsuits also assert that sales of low-T therapy were driven by marketing campaigns that wrongly positioned the medications as safe and effective remedies for low libido, weight gain and other issues commonly experienced by aging men.

Testosterone Risks, Benefits Still Unclear

The NEJM study involved nearly 800 men, age 65 and older, who were confirmed to have low testosterone levels. They were randomly assigned a testosterone gel, such as AndroGel, or a placebo gel, to use for one year. The subjects also filled out questionnaires and took a six-minute walking test.

Those treated with a low-T gel noted only modest improvements in sexual desire, and even less improvement with erectile dysfunction. While some men in the testosterone group did experience improvement in mood, there was no change in energy level or walking speed between the two groups.

In the end, the authors of the study were unable to recommend testosterone gels as a way to combat male aging.

“Making a recommendation depends on knowing all the benefits versus risks,” Dr. Peter Snyder, lead author of the study and a hormone specialist at the University of Pennsylvania, told the Associated Press. “We still don’t know everything we want to know.”

Despite their widespread use to alleviate symptoms associated with age-related drops in testosterone, prescription low-T therapies are only approved to treat hypogonadism related to another underlying medical condition. In March 2015, the U.S. Food & Drug Administration (FDA) ordered testosterone manufacturers to modify their labels to make it clear that the drugs have not been proven safe and effective in treating age-related hypogonadism. The agency also ordered that information be included on the labeling to warn of a potential association with an increased risk of heart attacks and strokes.

Testosterone Lawsuit Reviews

The nationwide law firm of Bernstein Liebhard LLP is currently representing plaintiffs in testosterone lawsuits. If you or a man you love experienced cardiovascular complications that could be associated with the use of AndroGel or another low-T therapy, please call 877-779-1414 to discuss your case with a member of our legal team.

Published March 3, 2016 by